mProX™ Human TYRO3 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

TYRO3, a member of the TAM (TYRO3, AXL, Mer) family of receptor tyrosine kinases, has been implicated in various physiological and pathological processes, including inflammation, adipocyte function, and autoimmune disorders. In the context of acute lung injury (ALI), TYRO3 has been shown to play a role in cell proliferation, apoptosis, and inflammatory response in pulmonary epithelial cells. In the study of human body fat distribution genes, TYRO3 was identified as a key driver gene that may regulate fat distribution by altering adipocyte function. In rheumatoid arthritis (RA), TYRO3 was found to contribute to the pathogenic phenotypes of fibroblast-like synoviocytes and disturb immune cell balance, suggesting it as a potential therapeutic target for RA. Additionally, TYRO3 has been recognized as a therapeutic target at the interface of cancer and immunity, as it promotes cell survival, metastasis, and resistance to therapy in cancer cells, while also suppressing antitumor immunity. Inhibition of TYRO3 has shown promise in preclinical and clinical studies as a potential cancer treatment strategy.